International Journal of Infectious Diseases · 2023 · 25 citations · 22 references
Veterinary MedicineImmunologyInfectious DiseasesEpidemiologyImmunizationVaccinologyAdult ImmunizationVaccinationVaccine EffectivenessVaccine EfficacyVaccine SafetyVaccine-preventable DiseasesAge-specific EfficacyAge-specific Vaccine EffectivenessOverall Vaccine EffectivenessPopulation-based Vaccine EffectivenessProspective Cohort DataSars-cov-2 InfectionSerologic Response To Booster VaccinationVaccine Effectiveness After Boosting
OBJECTIVES: We estimated vaccine effectiveness (VE) of primary and booster vaccinations against SARS-CoV-2 infection overall and in four risk groups defined by age and medical risk condition during the Delta and Omicron BA.1/BA.2 periods. METHODS: VAccine Study COvid-19 is an ongoing prospective cohort study among Dutch adults. The primary end point was a self-reported positive SARS-CoV-2 test from July 12, 2021 to June 06, 2022. The analyses included only participants without a previous SARS-CoV-2 infection based on a positive test or serology. We used Cox proportional hazard models with vaccination status as the time-varying exposure and adjustment for age, sex, educational level, and medical risk condition. RESULTS: A total of 37,170 participants (mean age 57 years) were included. In the Delta period, VE <6 weeks after the primary vaccination was 80% (95% confidence interval 69-87) and decreased to 71% (65-77) after 6 months. VE increased to 96% (86-99) shortly after the first booster vaccination. In the Omicron period, these estimates were 46% (22-63), 25% (8-39), and 57% (52-62), respectively. For the Omicron period, an interaction term between vaccination status and risk group significantly improved the model (P <0.001), with generally lower VEs for those with a medical risk condition. CONCLUSION: Our results show the benefit of booster vaccinations against infection, also in risk groups; although, the additional protection wanes quite rapidly.
22
Factors associated with COVID-19-related death using OpenSAFELY
Elizabeth Williamson, Alex J Walker, Krishnan Bhaskaran et al. · Nature · 2020 · 6.7K citations · Full text
Veterinary Medicine, Infectious Diseases, Clinical Epidemiology +6
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
Hung Fu Tseng, Bradley K. Ackerson, Yi Luo et al. · Nature Medicine · 2022 · 556 citations · Full text